donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > DYAI Dyadic > Financial Statement > Income statement
DYAI Dyadic
2.740
-0.080-2.84%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Total revenue
40.8% 648.43K 50.06% 2.4M -9.43% 313.29K 66.43% 692.93K
Operating revenue
40.8% 648.43K 50.06% 2.4M -9.43% 313.29K 66.43% 692.93K
Cost of revenue
3.58% 404.75K 36.46% 1.94M 29.76% 331.63K 47.06% 392.54K
Gross profit
249.32% 243.68K 159.56% 459.39K -120.3% -18.34K 101.02% 300.39K
Operating expense
-10.81% 3M 48.81% 15.09M 79.78% 4.18M 31.09% 3.59M
Selling and administrative expenses
6.54% 1.66M 10.07% 6.7M 29.75% 1.7M 3% 1.69M
-General and administrative expense
6.54% 1.66M 10.07% 6.7M 29.75% 1.7M 3% 1.69M
Research and development costs
-25.73% 1.34M 116.96% 8.39M 144.79% 2.47M 92.84% 1.9M
Operating profit
16.32% -2.75M -46.84% -14.63M -87.88% -4.19M -27.06% -3.29M
Net non-operating interest income expense
-88.44% 2.97K -88.43% 51.7K -96.5% 1.93K -95.83% 3.2K
Non-operating interest income
-88.44% 2.97K -88.43% 51.7K -96.5% 1.93K -95.83% 3.2K
Other net income (expense)
1020.51% 260.25K 578.45% 1.51M -108.37% -20.81K 9601.54% 1.58M
Gain on sale of security
136.25% 10.25K 578.45% 1.51M 537.25% 1.58M -284.74% -30K
Other non- operating income (expenses)
-- 250K -- -- -- -- -- 1.61M
Income before tax
24.38% -2.49M -40.63% -13.07M -118.46% -4.21M 31.38% -1.72M
Income tax
0
Net income
24.38% -2.49M -40.16% -13.07M -114.97% -4.21M 31.38% -1.72M
Net income continuous Operations
24.38% -2.49M -40.16% -13.07M -114.97% -4.21M 31.38% -1.72M
Minority interest income
Net income attributable to the parent company
24.38% -2.49M -40.16% -13.07M -114.97% -4.21M 31.38% -1.72M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
24.38% -2.49M -40.16% -13.07M -114.97% -4.21M 31.38% -1.72M
Basic earnings per share
25% -0.09 -38.24% -0.47 -114.29% -0.15 33.33% -0.06
Diluted earnings per share
25% -0.09 -38.24% -0.47 -114.29% -0.15 33.33% -0.06
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
--Unqualified Opinion----

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
CEO: Emalfarb, Mark A.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...